Agnogenic Myeloid Metaplasia Presenting as Massive Pericardial Effusion due to Extramedullary Hematopoiesis

Vilaseca, J; Arnau, Josep Maria; Tallada, N; L, Bernado; Lopez-Vivancos, J.L.; Guardia, J.

doi:10.1159/000206337

Acta Haematol

1985

DOI: 10.1159/000206337

|View full text |Cite

Agnogenic Myeloid Metaplasia Presenting as Massive Pericardial Effusion due to Extramedullary Hematopoiesis

J Vilaseca¹,

Josep Maria Arnau²,

N Tallada³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1987

1995

Publication Types

Select...

Article6

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 10 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the first category may be included symptoms due to the initial proliferative features of the disease, such as hypermetabolism, thrombocytosis and, in a few cases, even polycythaemia; later the usual haematological features are those of a variable degree of marrow failure. In the second category, the effects of hypersplenism usually dominate the picture, but myeloid metaplasia may occur in unexpected sites such as the pericardium (Vilaseca et al 1985); the central nervous system (Ligumski, Polliack & Benbassat 1978a;Cornfield et al 1983) and other organ systems, as reviewed by Ward & Block (1971).…”

mentioning

confidence: 99%

Management of idiopathic myelofibrosis

Kelsey

Geary

1987

Clinical &Amp; Laboratory Haematology

View full text Add to dashboard Cite

mentioning

confidence: 99%

Management of idiopathic myelofibrosis

Kelsey

Geary

1987

Clinical &Amp; Laboratory Haematology

View full text Add to dashboard Cite

Malignancy-related pericardial effusion. 127 cases from the roswell park cancer institute

Wilkes

Fidias

Vaickus

et al. 1995

Cancer

153

View full text Add to dashboard Cite

Background. Malignancy‐related pericardial effusions may represent a terminal event in patients with therapeutically unresponsive disease. However, select patients with malignancies sensitive to available therapies may achieve significant improvement in palliation and long term survival with prompt recognition and appropriate intervention. Methods. From 1968 to 1994, 150 invasive procedures were performed for the treatment or diagnosis of pericardial effusion in 127 patients with underlying malignancies. These cases were reviewed retrospectively to best identify the clinical features, appropriate diagnostic workup, and optimal therapy for this complication of malignancy. Results. Dyspnea (81%) and an abnormal pulsus paradoxus (32%) were the most common symptoms. Echocardiography had a 96% diagnostic accuracy. Cytology and pericardial biopsy had sensitivities of 90% and 56%, respectively. Fifty‐five percent of all effusions were malignant comprising 71% of adenocarcinomas of the lung, breast, esophagus, and unknown primary site. In 57 patients, a malignant effusion could not be determined, and no definitive etiology could be established for 74% of these effusions. Radiation‐induced, infectious, and hemorrhagic pericarditis each were identified in fewer than 5% of cases. Conclusions. Subxyphoid pericardiotomy proved to be a safe and effective intervention that successfully relieved pericardial effusions in 99% of cases with recurrence and reoperation rates of 9% and 7%, respectively. Survival most closely was related to the extent of disease and its inherent chemo‐/radiosensitivity, with 72% of the patients who survived longer than 1 year having breast cancer, leukemia, or lymphoma.

show abstract

Myelofibrosis: A concise review of clinical and pathologic features and treatment

Smith¹,

Chelmowski²,

Szabo

1988

American J Hematol

View full text Add to dashboard Cite

This paper reviews and clarifies the current understanding of the clinical and pathologic features and treatment of MF. Recent investigations indicate that MF may be mediated by platelet- and megakaryocyte-derived growth factors, impaired prostaglandin-mediated stem cell growth inhibition, or excessive endothelial cell and fibroblast proliferation. Immunologic disorders have been associated with MF. MF may be either a primary or a secondary phenomenon. Secondary MF often regresses with appropriate treatment of this underlying disorder. Primary MF may require androgen therapy, splenectomy, splenic irradiation, bone curettage, chemotherapy, or bone marrow transplantation.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Agnogenic Myeloid Metaplasia Presenting as Massive Pericardial Effusion due to Extramedullary Hematopoiesis

Cited by 10 publications

References 5 publications

Management of idiopathic myelofibrosis

Management of idiopathic myelofibrosis

Malignancy-related pericardial effusion. 127 cases from the roswell park cancer institute

Myelofibrosis: A concise review of clinical and pathologic features and treatment

Contact Info

Product

Resources

About